



NEWS RELEASE

Media Contacts:

Heidi Charalambous

(864) 512-3765

heidi.charalambous@anmedhealth.org

AnMed Health announces ALERTS Pivotal Study for implantable cardiac monitor and alert system

New study evaluates the safety and effectiveness of an implantable device, designed to reduce patient time to the ER and improve survival rates from heart attack in high-risk patients.

(Anderson, S.C. – April 3, 2012) – AnMed Health was recently approved to become the first study site in South Carolina for the ALERTS Pivotal US trial for the AngelMed Guardian implantable cardiac monitor and alert system. The system is designed to reduce the time it takes patients to get to the emergency room during an impending heart attack.

The AngelMed Guardian system is designed to track significant changes in the heart's electrical signal and then alert patients to seek medical attention. The goal of the ALERTS Pivotal Study is to provide an assessment of the safety and effectiveness of the AngelMed Guardian System.

“If the Guardian system proves to be effective in early detection and warning of potentially life-threatening heart conditions, we may be able to shift the paradigm for early treatment at the onset of heart attacks,” said Dr. Satish Surabhi, medical director of AnMed Health’s heart catheterization lab. “We are excited to participate in this important clinical trial.”

According to the American Heart Association, one of every five deaths in the United States is caused by coronary heart disease. Further, 50 percent of heart attack fatalities occur within one hour of symptom onset and occur before the patient even reaches the hospital.

"Experimental and clinical studies have shown that most of the damage to the heart occurs two hours after coronary occlusion," said David R. Fischell, CEO of AngelMed. "We've designed the device to warn patients of this and other cardiac events hours — perhaps days — before they occur."

The AngelMed Guardian System is comprised of an internal implantable device about the size of a standard pacemaker with a lead into the heart, an external telemetry device, and a programmer that aids physicians in evaluating heart signals.

“When someone has a heart attack, it is typically the result of a blood clot closing one of the three major coronary arteries. When this happens, there is a shift in the ST segment of the heart signal caused by the electrical difference between the portion of the heart muscle fed by the closed artery and the rest of the heart that is still receiving oxygen,” said David Fischell, PhD, CEO of AngelMed. “The ALERTS trial is designed to test the Guardian's ability to detect this electrical shift in a clinical setting and then provide an early warning to patients that could potentially save their lives.”

AnMed Health is among the first medical facilities to participate in the AngelMed Guardian system trial. To participate in the ALERTS study, patients must meet various inclusion criteria. For more information on the AngelMed Guardian system or the ALERTS study protocol, contact Charlesa Davis, RN, at 864-512-1291.

Forward Looking Statements: *Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes or benefits are forward-looking statements. A number of risks and uncertainties such as risks associated with product development and commercialization efforts, results of clinical trials, ultimate clinical outcomes and benefit of the Company's products to patients, market and physician acceptance of the products, intellectual property protection and competitive product offerings could cause actual events to adversely differ from the expectations indicated in these forward looking statements.*

###